Medacta Group (MOVE) Q4 2025 TU earnings summary

Executive summary

• FY 2025 revenue reached €683.8 million, representing 18.5% year-over-year growth in constant currency and 15.8% in Euro, with all business lines and geographies contributing and growth outpacing the market by 4.3x.

• Growth was driven by innovative product launches, personalized medical education, minimally invasive techniques, and significant team expansion, including 258 new hires.

• Acquisition of Parcus Medical in March 2025 strengthened the sports medicine and extremities portfolio, contributing 1.5% to total revenue.

• All regions and business lines contributed, with knee sales surpassing hip sales for the first time.

• Notable performance in APAC, North America, and Latin America, with strong growth in Extremities and Knee segments.

Financial highlights

• Revenue rose to €683.8 million from €590.6 million year-over-year, growing 18.5% in constant currency and 15.8% in Euro.

• Group revenue CAGR (2021–2025) was 17.4% in constant currency.

• Growth was 4.3x the market average, with all business lines and geographies contributing.

• Extremities business line grew 46.2% in constant currency, the highest among segments.

• Knee portfolio grew 20.7%, hip 11.9%, spine 12.2% (all in constant currency).

Outlook and guidance

• FY 2026 revenue growth targeted at 16% to 18% in constant currency, with adjusted EBITDA margin around 28% before currency effects, including the Parcus acquisition.

• Mid-term (2024–2027E) revenue CAGR expected between 10% and 14%, with adjusted EBITDA margin targeted at 28%.

• Full year audited results to be announced on 13 March 2026.

• Future outlook and midterm guidance updates will be communicated in March with full-year results.